{"id":62850,"date":"2026-04-29T00:31:17","date_gmt":"2026-04-28T22:31:17","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/cd177-promotes-nlr-inflammasome-activation-in-acute-respiratory-distress-syndrome-by-remodeling-neutrophil-glycolytic-metabolismdongfeng-shen-on-28-de-april-de-2026-at-1000\/"},"modified":"2026-04-29T00:31:17","modified_gmt":"2026-04-28T22:31:17","slug":"cd177-promotes-nlr-inflammasome-activation-in-acute-respiratory-distress-syndrome-by-remodeling-neutrophil-glycolytic-metabolismdongfeng-shen-on-28-de-april-de-2026-at-1000","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/cd177-promotes-nlr-inflammasome-activation-in-acute-respiratory-distress-syndrome-by-remodeling-neutrophil-glycolytic-metabolismdongfeng-shen-on-28-de-april-de-2026-at-1000\/","title":{"rendered":"CD177 Promotes NLR Inflammasome Activation in Acute Respiratory Distress Syndrome by Remodeling Neutrophil Glycolytic Metabolism\u200bDongfeng Shen   on 28 de April de 2026 at 10:00"},"content":{"rendered":"<div>\n<p><b>J Leukoc Biol<\/b>. 2026 Apr 21:qiag051. doi: 10.1093\/jleuko\/qiag051. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Acute respiratory distress syndrome (ARDS) is a high-mortality lung disorder driven by excessive neutrophil activation. While neutrophils are central to ARDS, the metabolic pathways fueling their inflammatory response remain unclear. This study identifies CD177 as a critical regulator of neutrophil glycolysis and NLRP3 inflammasome activation. Bioinformatics and animal models show that elevated CD177 correlates strongly with increased lactate and IL-1\u03b2 levels. In vitro experiments demonstrate that CD177 knockdown reduces glycolytic flux and suppresses IL-1\u03b2 release, a process reversed by lactate supplementation. Furthermore, treating ARDS mice with anti-CD177 antibodies significantly reduces pulmonary edema and tissue injury. These results establish the CD177-glycolysis-NLRP3 axis as a major driver of lung inflammation. Targeting this metabolic checkpoint provides a promising strategy for treating ARDS.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42047316\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=8405628&amp;ff=20260428183117&amp;v=2.19.0.post6+133c1fe\">42047316<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jleuko\/qiag051\">10.1093\/jleuko\/qiag051<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Leukoc Biol. 2026 Apr 21:qiag051. doi: 10.1093\/jleuko\/qiag051. Online ahead of print. ABSTRACT Acute respiratory distress syndrome (ARDS) is a high-mortality lung disorder driven by excessive neutrophil activation. While neutrophils are central to ARDS, the metabolic pathways fueling their inflammatory response remain unclear. This study identifies CD177 as a critical regulator of neutrophil glycolysis and &#8230; <a title=\"CD177 Promotes NLR Inflammasome Activation in Acute Respiratory Distress Syndrome by Remodeling Neutrophil Glycolytic Metabolism\u200bDongfeng Shen   on 28 de April de 2026 at 10:00\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/04\/29\/cd177-promotes-nlr-inflammasome-activation-in-acute-respiratory-distress-syndrome-by-remodeling-neutrophil-glycolytic-metabolismdongfeng-shen-on-28-de-april-de-2026-at-1000\/\" aria-label=\"Read more about CD177 Promotes NLR Inflammasome Activation in Acute Respiratory Distress Syndrome by Remodeling Neutrophil Glycolytic Metabolism\u200bDongfeng Shen   on 28 de April de 2026 at 10:00\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86,42],"tags":[],"class_list":["post-62850","post","type-post","status-publish","format-standard","hentry","category-journal-of-leukocyte-biology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=62850"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/62850\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=62850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=62850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=62850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}